조혈모세포 이식을 받은 소아 환자에서 cyclosporine의 집단 약동학 분석
Population Pharmacokinetics of Cyclosporine after Hematopoietic Stem Cell Transplantation in Pediatric Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Cyclosporine is an immunosuppressive agent used to treat and prevent graft versus host reaction (GVHR)−a complication associated with stem cell transplantation. This study aimed to develop a population pharmacokinetic model of cyclosporine and investigate factors affecting cyclosporine clearance in pediatric hematopoietic stem cell transplant patients. Methods: A total of 650 cyclosporine concentrations recorded in 65 patients who underwent hematopoietic stem cell transplantation were used. Data including age, sex, weight, height, body surface area (BSA), type of disease, chemotherapy before stem cell transplantation, type of donor, serum creatinine levels, total bilirubin concentration, hematocrit value, and type of concomitant antifungal agents and methylprednisolone used were retrospectively collected. Data related to cyclosporine dosage, administration time, and blood concentration were also collected. All data were analyzed using the non-linear mixed effect model; a twocompartment model with first-order elimination was used. Results: The population pharmacokinetic model of cyclosporine using the NONMEM program was as follows: CL (L/h) = 5.9 × (BSA / 1.2)0.9, V2 (L) = 54.5, Q (L/h) = 3.5, V3 (L) = 1080.0, ka (h-1) = 0.000377. BSA was selected as a covariate of cyclosporine clearance, which increased with an increase in BSA. Conclusion: A population pharmacokinetic model for Korean pediatric hematopoietic stem cell transplant patients was developed, and the important factor affecting cyclosporine clearance was found to be BSA. The model might contribute to the development of the most appropriate dosing regimen for cyclosporine. Further studies on population pharmacokinetics should be carried out, prospectively targeting pediatric patients.
Abstract
Background: Cyclosporine is an immunosuppressive agent used to treat and prevent graft versus host reaction (GVHR)−a complication associated with stem cell transplantation. This study aimed to develop a population pharmacokinetic model of cyclosporine and investigate factors affecting cyclosporine clearance in pediatric hematopoietic stem cell transplant patients. Methods: A total of 650 cyclosporine concentrations recorded in 65 patients who underwent hematopoietic stem cell transplantation were used. Data including age, sex, weight, height, body surface area (BSA), type of disease, chemotherapy before stem cell transplantation, type of donor, serum creatinine levels, total bilirubin concentration, hematocrit value, and type of concomitant antifungal agents and methylprednisolone used were retrospectively collected. Data related to cyclosporine dosage, administration time, and blood concentration were also collected. All data were analyzed using the non-linear mixed effect model; a twocompartment model with first-order elimination was used. Results: The population pharmacokinetic model of cyclosporine using the NONMEM program was as follows: CL (L/h) = 5.9 × (BSA / 1.2)0.9, V2 (L) = 54.5, Q (L/h) = 3.5, V3 (L) = 1080.0, ka (h-1) = 0.000377. BSA was selected as a covariate of cyclosporine clearance, which increased with an increase in BSA. Conclusion: A population pharmacokinetic model for Korean pediatric hematopoietic stem cell transplant patients was developed, and the important factor affecting cyclosporine clearance was found to be BSA. The model might contribute to the development of the most appropriate dosing regimen for cyclosporine. Further studies on population pharmacokinetics should be carried out, prospectively targeting pediatric patients.
참고문헌 (18)
- Horwitz ME, "Stem-cell transplantation for inherited immunodeficiency disorders", Pediatr Clin North Am, 47(6), pp.171~187 (2000)[DOI]
- Patzer L, "Renal function following hematological stem cell transplantation in childhood", Pediatr Nephrol, 18(7), pp.623~635 (2003)
- Baird K, "Chronic graft-versus-host disease (GVHD) in children", Pediatr Clin North Am, 57(1), pp.297~322 (2010)[DOI]
- Cheuk DK, "Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation", Bone Marrow Transplant, 40(10), pp.935~944 (2007)
- Jacobsohn DA, "Acute graft-versus-host disease in children", Bone Marrow Transplant, 41(2), pp.215~221 (2008)[DOI]
- Fahr A, "Cyclosporin clinical pharmacokinetics", Clin Pharmacokinet, 24(6), pp.472~495 (1993)[DOI]
- Del Mar Fernandez De Gatta M, "Immunosuppressive therapy for pediatric transplant patients: Pharmacokinetic considerations", Clin Pharmacokinet, 41(2), pp.115~135 (2002)[DOI]
- Dupuis LL, "Disposition of two oral formulation of cyclosporine in pediatric patients receiving hematopoietic stem cell transplants", Pharmacotherapy, 26(1), pp.15~22 (2006)[DOI]
- Oellerich M, "Lake Louise consensus conference on cyclosporine monitoring in organ transplantation: report of the consensus panel", Ther Drug Monit, 17(6), pp.642~654 (1995)[DOI]
- Belitsky P, "Impact of absorption profiling on efficacy and safety of cyclosporine therapy in transplant recipients", Clin Pharmacokinet, 39(2), pp.117~125 (2000)[DOI]
- Pal Falck, "A population pharmacokinetic model of cyclosporin applicable for assisting dose management of kidney transplant recipients", Clin pharmacokinet, 48(9), pp.615~623 (2009)[DOI]
- Rousseau A, "Population pharmacokinetic modeling of oral cyclosporin using NONMEM", Ther Drug Moni, 26(1), pp.23~30 (2004)[DOI]
- Sun B, "Population pharmacokinetic study of cyclosporine based on NONMEM in Chinese liver transplantation recipients", Ther Drug monit, 32(6), pp.715~722 (2010)[DOI]
- Fanta S, "Developmental pharmacokinetics of ciclosporin-a population pharmacokinetic study in paediatric renal transplant candidates", Br J Clin Pharmacol, 64(6), pp.772~784 (2007)
- Irtan S, "Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients", Ther Drug Monit, 29, pp.96~102 (2007)[DOI]
- Willemze AJ, "Ciclosporin kinetics in children after stem cell transplantation", Br J Clin Pharmacol, 66(4), pp.539~545 (2008)[DOI]
- Jacobson PA, "Posttransplant day significantly influences pharmacokinetics of cyclosporine after hematopoietic stem cell transplantation", Bio Blood Marrow Transplantation, 9(5), pp.304~311 (2003)[DOI]
- 김승희, "조혈모세포이식을 받은 한국 성인 백혈병환자에서 cyclosporine의 집단약동학 분석", 한국임상약학회지, 20(1), pp.9~16 (2010), 한국임상약학회